Oncology

Study authors note that additional research is necessary to confirm findings and identify biological pathways of associations between sweetened beverages and diseases of the liver.

Niraparib and abiraterone acetate (Akeega; Janssen Pharmaceutical Companies of Johnson & Johnson) is the first-and-only dual action tablet that combines a PARP inhibitor with abiraterone acetate administered with prednisone.

In the COLUMBUS study, the FDA requested that the investigators evaluate the contribution of binimetinib while maintaining the same dosage of encorafenib at 300 mg to confirm the benefits of the combination.

Precision therapies, although effective in earlier stages, may not work later.

Findings may have therapeutic implications because of the potential to target neurotransmitters to treat or prevent melanoma.

Microgravity provides researchers with a unique environment for studying how cells behave differently than they do on Earth.

Talquetamab-tgvs (Talvey) is a first-in-class bispecific antibody that binds to GPRC5D and CD3 to induce T cell-mediated killing of GPRC5D-expressing multiple myeloma cells.

With the continued advancement and approval of cell and gene therapies, the need for trustworthy microbiology quality control solutions is at an all-time high.

After carboplatin joined the growing list of drug shortages, staff pharmacists acted to minimize the impact on patients.

Researchers found an increase in patients with melanoma who experience chronic immune-related adverse effects at 18 months compared to a previous study with a follow-up point of 6 months.

Pharmacists will play a significant role in TKI adherence rates among patients.

Adding human papillomavirus genotypes to the predictive model had a significantly higher effect in improving accuracy compared to adding epidemiological factors and pelvic examination.

Although additional studies are needed, findings indicate that mtDNAfb may be a useful biomarker for future risk of non-Hodgkin lymphoma.

Though an association was found between depression and anxiety and lung cancers, there were no connections found to overall, breast, prostate, colorectal, and alcohol-related cancers.

Lisaftoclax is a novel, oral, small-molecule, BCL-2 selective inhibitor being evaluated for treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Study finds patients with cancer feel reassured that biosimilars provide a safe, adequate, and cost-effective alternative to the pricier reference drug.

Early safety studies of NK-cell infusion have demonstrated the potential of NK-cell infusion, showing it may be the next revolution in cancer treatment.

At a median follow-up of 48.7 months, pembrolizumab monotherapy produced an investigator-assessed objective response rate of 41.5% and a 20.8% complete response rate in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.

The affect of an aerobic exercise program was more prevalent in patients with ovarian cancer who had at least 1 symptom of chemotherapy-induced peripheral neuropathy at the beginning of the trial.

There are currently no HER2-directed therapies for many HER2-expressing solid tumors that are refractory.

With a better understanding of the underlying pathophysiology of chronic lymphocytic leukemia and the introduction of novel targeted agents, such as Bruton kinase Inhibitors, the prognosis of high-risk patients has changed dramatically.

microRNAs have shown potential to be used as biomarkers for diagnosing and treating different types of cancers, though their application in doing so had yet to be determined.

Dostarlimab-gxly (Jemperli) approved in combination with carboplatin and paclitaxel for the treatment of adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient.

Although approximately 95% of online drug sellers operate illegally, many consumers may never know the medications they receive are not what they claim to be.

There is much to be learned and progress to be made in all these efforts toward the optimization of tolerability, safety, and efficacy of oncologic therapies.

Investigators identified a specific subgroup of patients with mantle cell lymphoma who were at higher risk by defining a combination of MIPI, Ki-67, and p53/TP53 alternations.

The trial was recommended to continue to analyze event-free survival rates, but current results are encouraging for treating estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

Patient retraces her treatment journey from diagnosis through treatment for glioblastoma.

It was previously undetermined whether the combination of IVIG and ICI would lead to patient complications or reduced efficacy of the cancer treatment, but 2 successful case reports dispel that belief.